prepare icu@umcutrecht.nl

July 2017

NEWSLETTER

Pneumonia

Prof. Dr. Marc Bonten (Principal Investigator) &

Dr. Lennie Derde (Coordinating investigator for Europe)





omo(-9A) tenieg

Ms. Wilma van Bentum-Puijk (Project Manager) Dr. Sebastiaan Hullegie (Junior Project Manager)





Ms. Marloes van der Hagen (Clinical Trial Administrator) Ms. Wietske Bouwman (Clinical Trial Administrator)





New Name, Same Study

The previous AD-SCAP trial has been transformed into the REMAP-CAP study. The new name suits this international trial and the innovative study design better, and reflects a make-over of the protocol and full integration between different regions of the world. With currently 3 different grants, REMAP-CAP uses identical protocol, data collection and procedures in 3 global regions (EU, Australia, New-Zealand). The REMAP design provides the capacity to add new domains to the ongoing study and therefore has the ability to serve as an ongoing research platform.

An International Research Platform

The goal of REMAP-CAP is to improve treatment of patients with severe community acquired pneumonia (CAP), and to create a platform for the treatment of CAP in Intensive Care Units in Europe and around the world. This platform will also facilitate research in the setting of a pandemic.

Your Team in Utrecht

Since January 2017 we have been recruiting sites in Europe to participate in the REMAP-CAP study. As some of you may not be familiar with the research team at UMC Utrecht - the Coordinating Center for REMAP-CAP in Europe – we would like to introduce some of our main contacts on the left side of this newsletter. The UMC Utrecht closely collaborates with the REMAP-CAP Coordinating Centers in Australia and New Zealand.

We Need You!

We hope you share our enthusiasm for research, and our aim to provide better care for patients with CAP in the ICU. Please contact us and join this global initiative now!

Our study team will guide you through the set-up process, and will help you to get ready for your first inclusion. We look forward to working with you.